Experimental CAR-T therapy targets tough brain diseases
NCT ID NCT07341828
First seen Jan 23, 2026 · Last updated May 10, 2026 · Updated 21 times
Summary
This early-phase study tests a new treatment called C-CAR168, made from a patient's own immune cells, for people with severe central nervous system autoimmune diseases like multiple sclerosis and neuromyelitis optica that haven't responded to standard treatments. The therapy targets two proteins (CD20 and BCMA) to help control the disease. The main goal is to check safety and find the right dose in 15 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.